Indegene Limited
It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.
What Indegene files
- Others70
- Investor Meet67
- Updates40
- Important23
- JV/Acquisition10
- Board Meeting8
Indegene reported FY26 revenue of INR 3,510.5 Cr (up 23.6%) and PAT of INR 401.1 Cr. The company increased its dividend to INR 2.25/share. Strategic focus on AI-led operating models and integration of BioPharm (INR 882 Cr acquisition) is key for future growth and margin expansion.
Indegene reported strong results with revenue at ₹1063.1 Cr, up 39.7% YoY. PAT rose 45.9% QoQ to ₹116.2 Cr. Active clients expanded to 105, while 12 customers now exceed $10M. Revenue per employee hit $77.1K, highest among peers.
Indegene's 28th Annual General Meeting is on Thursday, 13 August 2026, at 4:30 PM IST via VC/OAVM. Annual Report for FY25-26 links sent to shareholders lacking registered emails. Physical share holders urged to update KYC for seamless electronic payments.
Indegene's FY26 BRSR details strong ESG progress: 20.63% reduction in Scope 1&2 GHG emissions and 68.68% in Scope 3. Women comprise 46% of workforce; zero info security/bribery incidents. Company turnover ₹1,220.6 Cr.
Indegene recognized as a Leader in ISG Provider Lens™ for Life Sciences Digital Services in Commercial Operations for the 3rd consecutive year. This underscores its strong domain expertise and AI-embedded platforms, driving data-driven commercial operations for life sciences clients. A significant business development.